Looking Ahead: Immunotherapy's Role, Unmet Needs, and What the Panel Is Watching

In this final segment, the panel reflects on where the field stands and what they are most closely watching as the treatment landscape for EGFR-mutant non-small cell lung cancer continues to evolve. You will hear an honest assessment of why checkpoint inhibitors have largely failed in this disease subtype and what would need to change for immune-based approaches to find a role, including the risk of subsequent pulmonary toxicity that has kept many clinicians from using them. The panel then looks ahead to what they believe will make the biggest difference for patients, from fourth-generation agents targeting secondary resistance mutations to novel immune modulators and neoadjuvant approaches. Each panelist closes with a single takeaway for clinicians managing this disease, emphasizing individualized care, the pace of progress in the exon 20 space, and the importance of staying current in a rapidly evolving field.